Assenagon Asset Management S.A. boosted its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 8.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 104,392 shares of the medical instruments supplier's stock after purchasing an additional 8,102 shares during the period. Assenagon Asset Management S.A. owned about 0.15% of Insulet worth $27,254,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Baillie Gifford & Co. boosted its holdings in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock worth $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Geode Capital Management LLC raised its position in Insulet by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock valued at $403,339,000 after purchasing an additional 22,850 shares during the last quarter. Clearbridge Investments LLC boosted its stake in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier's stock worth $270,364,000 after purchasing an additional 75,526 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after buying an additional 163,388 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock valued at $148,091,000 after buying an additional 193,839 shares in the last quarter.
Insulet Stock Up 1.1 %
Shares of NASDAQ:PODD traded up $2.95 during trading on Friday, hitting $275.81. 554,098 shares of the company's stock traded hands, compared to its average volume of 525,927. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market cap of $19.35 billion, a price-to-earnings ratio of 47.23, a price-to-earnings-growth ratio of 3.41 and a beta of 1.22. The company has a 50-day moving average price of $266.15 and a 200-day moving average price of $231.90. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.77.
Analyst Ratings Changes
A number of equities research analysts have commented on PODD shares. Sanford C. Bernstein assumed coverage on shares of Insulet in a report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price objective on the stock. BTIG Research increased their price target on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Wells Fargo & Company upped their price objective on Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Morgan Stanley upped their price target on Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Finally, Barclays upped their target price on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $272.81.
Check Out Our Latest Stock Report on PODD
Insider Activity
In other Insulet news, CAO Lauren Budden sold 915 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.47% of the company's stock.
Insulet Company Profile
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Featured Articles
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.